Blog

– Platform Enables Customers to Manufacture mRNA with Substantial Reduction in dsRNA and Manufacturing Complexities; Integrable into Current mRNA Workflows – – Platform Currently Available Under Early Access Program –   STONY BROOK, N.Y. – July 13, 2023 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in PCR-based DNA […]

A novel approach of using a DNA therapeutic platform with a Lipid Nanoparticle (LNP)-based delivery system and focused on veterinary vaccine applications has been evaluated and our preliminary results are reported in this white paper. The studies shown herein support the advancement of high-fidelity, PCR-produced linearDNA™ in vaccine applications, taking advantage of linearDNA’s rapid design, […]

STONY BROOK, N.Y. – March 29, 2023 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in PCR-based DNA technologies, today announced that it has established a new high bar for the production of DNA with the manufacture and shipment of a multi-gram quantity of linearDNA™ in under six weeks. The quantity was […]

The study, titled ‘A linear DNA vaccine candidate encoding the SARS-CoV-2 Receptor Binding Domain elicits protective immunity in domestic cats,’ supports the further development of the Company’s LinearDNA™ platform for the large-scale enzymatic (PCR, polymerase chain reaction) production of prophylactic and therapeutic linearDNA™-based vaccines.

– Planned Doubling of Current DNA Production Capacity will Enable Company to Support Customers from Early-stage Drug Discovery Through Late-phase Clinical Trials – – Expansion Plans Catalyzed by Growing Industry Demand for LinearDNA™,  Repeat and New Proof-of-Concept Orders from Customers with Long-Term Requirements for cGMP DNA – Operational Commencement Expected in 2H CY2023 – STONY […]

STONY BROOK, N.Y. – October 10, 2022 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in PCR-based DNA technologies, announced today that it received its largest single purchase order for LinearDNA™ valued above the mid-six-figures. The order was placed under a long-standing supply agreement for the bulk manufacture of LinearDNA for a […]

Promising Results Support Further Development of LinearDNA as a Next Generation Vaccine Platform STONY BROOK, N.Y. – September 26, 2022 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (‘Applied DNA’ or the “Company”), a leader in polymerase chain reaction (PCR”)-based technologies, today announced the publication of a manuscript, co-authored with international academic and industry scientists, containing […]

– Agreement Leverages Company’s Ability for Intramuscular Delivery of LNP-Encapsulated LinearDNA-based Therapies for Veterinary Therapeutic and Prophylactic Applications – STONY BROOK, N.Y. and ITHICA, N.Y. – September 8, 2022 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (‘Applied DNA’ or the “Company”), a leader in polymerase chain reaction (“PCR”)-based technologies, and the Cornell University College of […]

– Use of LNP Simplifies Administration of LinearDNA-based Therapies, Potentially Enabling Their Application in Large Scale – STONY BROOK, N.Y. – August 10, 2022 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in polymerase chain reaction (“PCR”)-based technologies, today announced that LineaRx, the Company’s majority-owned biotherapeutics subsidiary, has for the first time […]

Proprietary, highly efficient and scalable linDNA (linear DNA, the product of PCR) manufacturing process for use in nucleic acid-based therapies. Learn how LineaRx is the common denominator of next-generation therapies.